XCancer
Novartis

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Description:

The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals (STUDY_DIRECTOR)

Novartis Pharmaceuticals (CONTACT)

Novartis Pharmaceuticals (CONTACT)

novartis.email@novartis.com

+41613241111

Government Study Link:

NCT06517719 - Click here to see study on

ClinicalTrials.gov

PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • ≥ 18 years old at the time of enrollment
  • Written informed consent must be obtained prior to any data collection
  • Willing to participate in Quality of Life post treatment date collection for 1 year
  • All patients must meet the following inclusion criteria during the identification period:
  • Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
Exclusion
  • Patients must not meet the following exclusion criterion during the identification period:\- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan